Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 21st World Congress on Gastrointestinal Cancer /
TRIBE2: Latest data for patients with mCRC

3rd - 7th Jul 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.07.19
Views: 550
Rating:

Dr Chiara Cremolini - Università di Pisa, Pisa, Italy

Dr Chiara Cremolini speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about the TRIBE2 updated results.

She reports that the trial met its primary endpoint of prolonged second progression-free survival in the arm of unresectable metastatic colorectal cancer (mCRC) patients treated with upfront FOLFOXIRI plus bevacizumab followed by the pre-planned reintroduction of the same agents after disease progression.

Dr Cremolini outlines how the toxicity profiles varied and what these latest results mean for clinical practice in the future.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation